136-17-4

Basic information

• Product Name: 2,4-DIAMINODIPHENYLAMINE
• Synonyms: 4-benzenetriamine,n(sup1)-phenyl-2;2,4-DIAMINODIPHENYLAMINE;4-Phenylaminobenzene-1,3-diamine;N'-Phenyl-1,2,4-benzenetriamine;N-Phenyl-1,2,4-benzenetriamine;(2,4-diaminophenyl)-phenyl-amine;1-N-phenylbenzene-1,2,4-triamine;N1-phenylbenzene-1,2,4-triamine
• CAS NO: 136-17-4
• Molecular Formula: C₁₂H₁₃N₃
• Molecular Weight: 199.25
• Mol File: 136-17-4.mol
• Article Data: 6

Chemical Properties

• Melting Point: 129-131°C
• Boiling Point: 389.1°Cat760mmHg
• Flash Point: 223.3°C
• Appearance: /
• Density: 1.245g/cm³
• Vapor Pressure: 2.91E-06mmHg at 25°C
• Refractive Index: 1.733
• PKA: 5.19±0.10(Predicted)
• CAS DataBase Reference: 2,4-DIAMINODIPHENYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-DIAMINODIPHENYLAMINE(136-17-4)
• EPA Substance Registry System: 2,4-DIAMINODIPHENYLAMINE(136-17-4)

Safety Data

• Statements: 33
• RIDADR: UN2811
• RTECS: DC1954000
• HazardClass: 6.1
• PackingGroup: III
• Hazardous Substances Data: 136-17-4(Hazardous Substances Data)

Usage

General Description

2,4-Diaminodiphenylamine, also known as DADPA, is a chemical compound widely used in the manufacturing industry. This light yellow to brown solid compound has a distinct amine odor and is primarily used in the production of dyes, antioxidants, pharmaceuticals, corrosion inhibitors, and rubber chemicals. When exposed to air, it may darken due to oxidation. It possesses unique chemical properties such as stability under ordinary conditions, flammability upon heating, and the ability to react with acids, acid chlorides, and acid anhydrides. Although useful in various industries, this chemical can be hazardous due to its toxicity. Its exposure can cause eye irritation, skin burns, respiratory disorders, and other health issues.

InChI:InChI=1/C12H13N3/c13-9-6-7-12(11(14)8-9)15-10-4-2-1-3-5-10/h1-8,15H,13-14H2

Upstream product

• 7647-01-0 hydrogenchloride 
• 961-68-2 N-phenyl-2,4-dinitroaniline 
• 70-34-8 2,4-Dinitrofluorobenzene 
• 100-65-2 N-Phenylhydroxylamine 
• 584-48-5 2,4-dinitrobromobenzene 
• 64-19-7 acetic acid 

Downstream Products

• 3018-68-6 1-phenyl-2-methyl-5-aminobenzimidazole 
• 851875-41-7 [4-({5-[2-(4-tert-butoxyoxalyl-phenoxy)-acetylamino]-2-phenylamino-phenylcarbamoyl}-methoxy)-phenyl]-oxo-acetic acid tert-butyl ester 
• 299927-16-5 N-(2-methyl-1-phenyl-1H-benzimidazol-5-yl)-acetamide 
• 1491162-60-7 N-(phenazin-2-yl)benzenesulfonamide 
• 304644-21-1 N-(phenazin-2-yl)benzamide 
• 1491162-53-8 N-(phenazin-2-yl)cyclohexanecarboxamide 
• 1491162-52-7 4-methoxy-N-(phenazin-2-yl)benzamide 
• 1491162-51-6 3-methyl-N-(phenazin-2-yl)benzamide 
• 1491162-50-5 2-methyl-N-(phenazin-2-yl)benzamide 
• 1491162-49-2 4-methyl-N-(phenazin-2-yl)benzamide 
• 1491162-48-1 3-chloro-N-(phenazin-2-yl)benzamide 
• 1491162-47-0 2-chloro-N-(phenazin-2-yl)benzamide 
• 1491162-46-9 N-(phenazin-2-yl)-2-phenylacetamide 
• 627469-49-2 2,2,2-trifluoro-N-(1-phenyl-2-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)acetamide 

Relevant articles and documents

Design, synthesis and biological evaluations of diverse Michael acceptor-based phenazine hybrid molecules as TrxR1 inhibitors

A series of novel phenazine derivatives (1~27) containing the Michael acceptor scaffolds were designed and synthesized in this study. Some compounds exhibited selective cytotoxicity against Bel-7402 cancer cell line in vitro, in which compound 26 were found to have the best antiproliferative activity. Meanwhile, compound 26 showed no obvious cell toxicity against human normal liver epithelial L02 cells, which means this compound possessed a better safety potential. In the following research, compound 26 was verified to inhibit TrxR1 enzyme activity, ultimately resulting in cellular molecular mechanism events of apoptosis including growth of intracellular ROS level, depletion of reduced Trx1, liberation of ASK1 and up-regulation of p38, respectively. Together, all these evidences implicated that compound 26 acted as the TrxR1 inhibitor against Bel-7402 cells, and could activate apoptosis through the ROS-Trx-ASK1-p38 pathway.

ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION

Compounds, methods and pharmaceutical compositions for treating viral : infections, by administering certain novel compounds in therapeutically effective "'" amounts are disclosed. Methods for preparing the compounds and method’s using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by hemorrhagic fever viruses is disclosed, i.e., including but not limited to, Arenaviridae (Junin, Machupo, Guanarito, Sabia, Lassa, Tacaribe, Pichinde, and LCMV), Filoviridae (Ebola and Marburg viruses), Flaviviridae (yellow fever, Omsk hemorrhagic fever and Kyasanur Forest disease viruses), and Bunyaviridae (Rift Valley fever).

INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AND TYPE 2

There is provided a compound having Formula (I): wherein one of R1 and R2 is a group of the Formula (a), wherein R4 is selected from H and hydrocarbyl, R5 is a hydrocarbyl group and L is an optional linker group, or R1 and R2 together form a ring substituted with the group (Formula (a)) wherein R3 is H or a substituent, and wherein X is selected from S, O, NR6 and C(R7)(R8), wherein R6 is selected from H and hydrocarbyl groups, wherein each of R7 and R8 are independently selected from H and hydrocarbyl groups.